At the news
? NEUTRALIMPACT 1/10 PRESS-RELEASE filed Jul 2, 2026 at 16:01 ET
Xenon Pharmaceuticals granted 20,200 stock options and 11,850 RSUs to four new non-officer employees as inducement equity awards under Nasdaq Rule 5635(c)(4), with an exercise price of $60.30 per share. The grants are routine retention tools for new hires and have negligible dilutive impact relative to the company's $5.8B market capitalization.
- Aggregate grants: 20,200 share options and 11,850 RSUs to four new non-officer employees
- Option exercise price: $60.30 per share, equal to July 1, 2026 closing price
- Options vest 25% at one-year anniversary, then monthly over 4 years; RSUs vest 25% annually over 4 years
- Grants approved by Compensation Committee as inducements material to employment per Nasdaq Rule 5635(c)(4)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access